全文获取类型
收费全文 | 1791篇 |
免费 | 93篇 |
国内免费 | 15篇 |
专业分类
耳鼻咽喉 | 22篇 |
儿科学 | 17篇 |
妇产科学 | 100篇 |
基础医学 | 155篇 |
口腔科学 | 25篇 |
临床医学 | 142篇 |
内科学 | 465篇 |
皮肤病学 | 27篇 |
神经病学 | 136篇 |
特种医学 | 41篇 |
外科学 | 332篇 |
综合类 | 9篇 |
预防医学 | 61篇 |
眼科学 | 60篇 |
药学 | 156篇 |
中国医学 | 3篇 |
肿瘤学 | 148篇 |
出版年
2024年 | 1篇 |
2023年 | 22篇 |
2022年 | 43篇 |
2021年 | 64篇 |
2020年 | 42篇 |
2019年 | 57篇 |
2018年 | 64篇 |
2017年 | 39篇 |
2016年 | 54篇 |
2015年 | 61篇 |
2014年 | 84篇 |
2013年 | 108篇 |
2012年 | 169篇 |
2011年 | 147篇 |
2010年 | 81篇 |
2009年 | 68篇 |
2008年 | 145篇 |
2007年 | 119篇 |
2006年 | 128篇 |
2005年 | 118篇 |
2004年 | 86篇 |
2003年 | 83篇 |
2002年 | 51篇 |
2001年 | 5篇 |
2000年 | 6篇 |
1999年 | 5篇 |
1998年 | 9篇 |
1997年 | 5篇 |
1996年 | 4篇 |
1995年 | 2篇 |
1994年 | 10篇 |
1993年 | 1篇 |
1992年 | 3篇 |
1991年 | 1篇 |
1989年 | 1篇 |
1988年 | 1篇 |
1987年 | 2篇 |
1983年 | 1篇 |
1982年 | 1篇 |
1981年 | 1篇 |
1980年 | 2篇 |
1979年 | 1篇 |
1978年 | 1篇 |
1977年 | 1篇 |
1976年 | 1篇 |
1972年 | 1篇 |
排序方式: 共有1899条查询结果,搜索用时 31 毫秒
91.
Athina Christopoulou Alexandros Ardavanis Christos Papandreou Georgios Koumakis Georgios Papatsimpas Pavlos Papakotoulas Nikolaos Tsoukalas Charalambos Andreadis Georgios Samelis Pavlos Papakostas Gerasimos Aravantinos Nikolaos Ziras Maria Souggleri Charalambos Kalofonos Epameinondas Samantas Paris Makrantonakis Georgios Pentheroudakis Athanasios Athanasiadis Helen Stergiou Alexandros Bokas Anastasios Grivas Elli-Sofia Tripodaki Ioannis Varthalitis Eleni Timotheadou Ioannis Boukovinas 《Oncology Letters》2022,23(4)
Thromboprophylaxis, as a preventive measure for cancer-associated thrombosis (CAT), may be beneficial for patients with active cancer and high-risk for thrombosis. The present post hoc analysis include a total of 407 patients enrolled in the Greek Management of Thrombosis study, who received thromboprophylaxis with tinzaparin. The objectives of the present analysis were: i) To obtain sufficient evidence for the administration of prophylaxis in patients with active cancer, irrespective of Khorana risk assessment model score; ii) to identify the selection criteria for both dose and duration of tinzaparin; and iii) to evaluate the efficacy and safety of tinzaparin administered for CAT prophylaxis. The main tumor types for the patients included in the present study were as follows: Lung (25.1%), pancreatic (14.3%), breast (9.1%), stomach (8.4%), colorectal (7.9%) and ovarian (7.6%). Furthermore, metastatic disease was observed in 69.5% of the patients. High thrombotic burden agents (HTBAs) were administered to 66.3% of the patients, and 17.4% received erythropoietin. A total of 43.7% of the patients exhibited a Khorana score <2. The results of the present study demonstrated that both the presence of metastatic disease and the use of HTBAs seemed to influence oncologists'' decisions for the use of thromboprophylaxis in patients with active cancer, regardless of Khorana score. Tinzaparin, in dose expressed in the standard notation for heparins, i.e., anti-Xa factor international units (Anti-Xa IU), was administered at an intermediate dose (InterD; 8,000-12,000 Anti-Xa IU; once daily) to 52.4% of patients, while the remaining patients received a prophylactic dose (ProD; ≤4,500 Anti-Xa IU; once daily). The average duration of thromoprophylaxis was 5 months. Furthermore, a total of 14 (3.4%) thrombotic events and 6 (1.5%) minor bleeding events were recorded. A total of four thrombotic events were observed following an InterD treatment of tinzaparin, while 10 thrombotic events were observed following ProD treatment. The present study also demonstrated that an InterD of tinzaparin was administered more frequently to patients with a body mass index >30 kg/m2, a history of smoking and a history of metastatic disease, along with administration of erythropoietin. InterD tinzaparin treatment was found to be potentially more efficacious and without safety concerns. The present study is a registered clinical trial (ClinicalTrials.gov code, ; registration date, September 25, 2017). NCT03292107相似文献
92.
Zachariadis Alexandros Tulbu Anca Strambo Davide Dumoulin Alexis Di Virgilio Gabriella 《Journal of neurology》2020,267(12):3459-3461
Journal of Neurology - 相似文献
93.
David J. Seiffge MD Gian Marco De Marchis MD Masatoshi Koga MD PhD Maurizio Paciaroni MD Duncan Wilson PhD Manuel Cappellari MD Kosmas Macha MD Georgios Tsivgoulis MD Gareth Ambler PhD Shoji Arihiro MD Leo H. Bonati MD Bruno Bonetti MD Bernd Kallmünzer MD Keith W. Muir MD PhD Paolo Bovi MD Henrik Gensicke MD Manabu Inoue MD Stefan Schwab MD Shadi Yaghi MD Martin M. Brown MD PhD FRCP Philippe Lyrer MD Masahito Takagi MD PhD Monica Acciarrese MD Hans Rolf Jager MD FRCP Alexandros A. Polymeris MD Kazunori Toyoda MD PhD Michele Venti MD Christopher Traenka MD Hiroshi Yamagami MD PhD Andrea Alberti MD Sohei Yoshimura MD PhD Valeria Caso MD Stefan T. Engelter MD David J. Werring MD PhD FRCP the RAF RAF-DOAC CROMIS- SAMURAI NOACISP Erlangen and Verona registry collaborators 《Annals of neurology》2020,87(5):677-687
94.
Christina Fytili Theodora Nikou Nikolaos Tentolouris Ioulia K. Tseti Charilaos Dimosthenopoulos Petros P. Sfikakis Dimitrios Simos Alexandros Kokkinos Alexios L. Skaltsounis Nikolaos Katsilambros Maria Halabalaki 《Nutrients》2022,14(7)
Hydroxytyrosol (HT) is a natural antioxidant found in olive products and characterized by well-documented beneficial effects on human health. Several research studies are ongoing that aim to investigate its potency and molecular mechanism of action. The present study aimed to investigate the potential effect of HT on human obesity through a randomized double-blind prospective design. HT in two different doses (15 and 5 mg/day) and a placebo capsule was administered to 29 women with overweight/obesity for six months and their weight and fat mass were monitored at three time points (baseline, 4, 12 and 24 weeks). Statistically significant weight and visceral fat mass loss (%weight loss: p = 0.012, %visceral fat loss: p = 0.006) were observed in the group receiving the maximum HT dosage versus placebo after 4 weeks of the intervention, with attenuation of these findings at 12 and 24 weeks of the study. Urine samples were collected during the intervention and analyzed via liquid chromatography–high-resolution mass spectrometry for untargeted metabolomic purposes and comparisons between study groups were performed. HT administration was safe and well-tolerated. To the best of our knowledge, this is the first human cohort investigating the effects of HT on obesity for a prolonged study period. 相似文献
95.
Serafeim Chlapoutakis Vasiliki Epameinondas Georgakopoulou Nikolaos Trakas Georgios Kouvelos Petros Papalexis Christos Damaskos Pagona Sklapani Anastasios Grivas Panagiotis Gouveris Dimitrios Tryfonopoulos Alexandros Tzovaras Gerasimos Ardavanis-Loukeris Elissavet Grouzi Demetrios A. Spandidos Miltiadis Matsagkas 《Oncology Letters》2022,23(5)
Pulmonary embolism (PE), along with deep vein thrombosis, are collectively known as venous thromboembolism (VTE). Predisposing factors for PE include post-operative conditions, pregnancy, cancer and an advanced age; of note, a number of genetic mutations have been found to be associated with an increased risk of PE. The association between cancer and VTE is well-established, and cancer patients present a higher risk of a thrombotic event compared to the general population. In addition, PE is a significant cause of morbidity and mortality among cancer patients. The aim of the present study was to illustrate the clinical characteristics, laboratory findings, radiology features and outcomes of cancer patients who developed PE, collected from an anticancer hospital. For this purpose, adult cancer patients diagnosed with PE by imaging with computed tomography pulmonary angiography were enrolled. The following data were recorded: Demographics, comorbidities, type of cancer, time interval between cancer diagnosis and PE occurrence, the type of therapy received and the presence of metastases, clinical signs and symptoms, predisposing factors for PE development, laboratory data, radiological findings, electrocardiography findings, and the type of therapy received for PE and outcomes in a follow-up period of 6 months. In total, 60 cancer patients were enrolled. The majority of the cancer patients were males. The most common type of cancer observed was lung cancer. The majority of cases of PE occurred within the first year from the time of cancer diagnosis, while the majority of patients had already developed metastases. In addition, the majority of cancer patients had received chemotherapy over the past month, while they were not receiving anticoagulants and had central obstruction. A large proportion of patients had asymptomatic PE. The in-hospital mortality rate was 13.3% and no relapse or mortality were observed during the follow-up period. The present study demonstrates that elevated levels of lactic acid and an increased platelet count, as well as low serum levels of carcinoembryonic antigen, albumin and D-dimer, may be potential biomarkers for asymptomatic PE among cancer patients. 相似文献
96.
97.
Jennifer Samuelsson Merete Sunila Alexandros Rentzos Daniel Nilsson 《The Neuroradiology Journal》2022,35(2):213
ObjectivesCerebral vasospasm is a known complication to aneurysmal subarachnoid haemorrhage, which can lead to severe morbidity. Intra-arterial vasodilation therapy is widely used as a last resort treatment in patients with symptomatic refractory cerebral vasospasm but there is limited data about the outcome. The purpose of this study is to evaluate the neurological and radiological outcome in patients treated with intra-arterial nimodipine in relation to cerebral infarction, procedure-related complications and clinical outcome.MethodsPatients with refractory cerebral vasospasm treated with intra-arterial nimodipine during 2009–2020 at Sahlgrenska University Hospital were retrospectively reviewed. Neurological outcome (modified Rankin Scale) at 30 days and 6 months, development of cerebral infarction after intra-arterial nimodipine treatment and procedure-related complications were studied.ResultsForty-eight patients were treated with intra-arterial nimodipine. A good outcome (modified Rankin Scale 0–2) was seen in 25% (n = 12) of the patients after 30 days and in 47% (n = 22) of the patients after six months. Infarction related to the vasospastic vessel after treatment with intra-arterial nimodipine was seen in 60% (n = 29) of the patients. A total of 124 procedures with intra-arterial nimodipine were performed where complications were seen in 10 (21%) patients in 10 (8%) procedures. Four (8%) patients died within 30 days.ConclusionsA majority of patients developed an ischaemic cerebral infarction in spite of intra-arterial nimodipine treatment. However, a good clinical recovery was seen in almost half of the patients after 6 months. Minor complications occurred in one out of five patients. 相似文献
98.
Alexandros Marios Sofias Francis Combes Steffen Koschmieder Gert Storm Twan Lammers 《Drug discovery today》2021,26(6):1482-1489
- Download : Download high-res image (101KB)
- Download : Download full-size image
99.
100.